首页> 外国专利> HUMAN INNATE LYMPHOID CELL PRECURSORS: IDENTIFICATION, CHARACTERIZATION, APPLICATIONS

HUMAN INNATE LYMPHOID CELL PRECURSORS: IDENTIFICATION, CHARACTERIZATION, APPLICATIONS

机译:人体先天淋巴细胞前体:鉴定,表征,应用

摘要

Innate lymphoid cells (ILCs) represent innate versions of T helper and cytotoxic T cells that differentiate from committed ILC precursors (ILCP). Still, how ILCP relate to mature tissue-resident ILCs remains unclear. ILCP that are present in the blood and all tested lymphoid and non-lymphoid human tissues were identified. Human ILCP fail to express the signature transcription factors (TF) and cytokine outputs of mature NK cells and ILCs but are epigenetically poised to do so. Human ILCP robustly generate all ILC subsets in vitro and in vivo. While human ILCP express RAR related orphan receptor C (RORC), circulating ILCP can be found in RORC-deficient patients that retain potential for EOMES+ NK cells, T-BET+ ILC1, GATA-3+ ILC2 and for IL-22+ but not for IL-17A+ ILC3. A model of tissue ILC differentiation (‘ILC-poiesis’) is proposed whereby diverse ILC subsets are generated in situ from ILCP in response to environmental stressors, inflammation and infection.
机译:先天淋巴细胞(ILCS)代表T辅助者和细胞毒性T细胞的先天版,其区分in ILC前体(ILCP)。尽管如此,ILCP如何与成熟的组织 - 驻地ILCs仍然不清楚。鉴定出存在于血液和所有测试的淋巴和非淋巴组织组织中的ILCP。人ILCP未能表达成熟的NK细胞和ILCS的签名转录因子(TF)和细胞因子产出,但表述是表现出的。人ILCP在体外和体内鲁棒地产生所有ILC子集。虽然人ILCP Express RAR相关的孤儿受体C(RORC),但循环ILCP可以在Rorc缺陷患者中发现,其保留eomes + nk细胞,T-bet + ILC1,GATA-3 + ILC2和IL-22 + 但不适用于IL-17a + / sup> ilc3。提出了一种组织ILC分化('ILC-POIESIS')的模型,其中各种ILC子集是从ILCP原位产生的,以应对环境压力,炎症和感染。

著录项

  • 公开/公告号US2021108177A1

    专利类型

  • 公开/公告日2021-04-15

    原文格式PDF

  • 申请/专利权人 INSTITUT PASTEUR;

    申请/专利号US201716463655

  • 发明设计人 JAMES DI SANTO;AI ING LIM;

    申请日2017-11-30

  • 分类号C12N5/0789;G01N33/50;A61K49;

  • 国家 US

  • 入库时间 2022-08-24 18:14:27

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号